[2015, July 10th] Submitting your R&D at MEDIT is now eligible for your company to the French CIR tax credit
On July 10th 2015, MEDIT got the the CIR agreement (Credit Impot Recherche) from the Ministère de l’Edutation Nationale, de l’Enseignement Supérieur et de la Recherche, ain reference to article 244 quarter B from tax law book. Submitting your discovery project to MEDIT r&D opens to your company a tax return up to 30% of the fees engaged with us.
[2014, Sept 1st] Oral presentation at 20th EuroQSAR 2014 Conference in Saint Petersburg
MEDIT in collaboration with SupBiotech and Felix Concordia presented recent R&D results at the EuroQSAR 2014 : “Cross-mining in 3D-2D-1D the PDB, chemical libraries and structure activities to extract shared modes of binding for PDB ligand substructures”.
[2014, July 2nd] RICT2014 conference: download our poster on FcBioisostere recent results
MEDIT, Felix Concordia SARL and SupBiotech are proud to present further statistical analysis and validations of the FcBioisostere software at the 50th International Conference on Medicinal Chemistry. Please look at our poster
[2013, July 1st] MEDIT at the 49th International Conference on Medicinal Chemistry (RICT)
MEDIT and Felix Concordia SARL are proud to present some early results about the C2P initiative (Chemo-Proteomic Platform) in a poster on Plasmodium falciparum kinases where biostructural data, SAR data and chemical libraries are cross-mined altogether thanks to the C2P Chemo-Proteomic Platform offer.
[2012, April 21] MEDIT at Experimental Biology 2012 conference
MEDIT is welcoming you at its booth at the Experimental Biology 2012 conference in San Diego. Get fresh news about hot products like MED-SuMo and FcBioisostere for biologics design, repurposing and ligand design !
[2012, March 25th] MEDIT at ACS meeting in San Diego
MEDIT is welcoming you at its booth at the ACS spring meeting in San Diego March 25-29. Get fresh news about hot products like MED-SuMo and FcBioisostere for biologics design, repurposing and ligand design ! Or just pass by to say hello to our booth.
[2012, March 1st] Medit is distributing FcBioisostere software
MEDIT is becoming a distributor to the FcBioisostere software developed by Felix Concordia SARL company. We recommand to use MED-SuMo for binding site superpositions to generate innovative set of Bioisosteric chemical pairs in FcBioisostere. MEDIT and Felix Concordia SARL believe in this new collaboration to provide broader solutions for the benefit of pharma industry.
For chemists and modelers, FC-Bioisostere software opens access to 3D bioisosteric replacement onto your molecule of interest to find chemical groups having similar 3D biological interactions. While maintaining target potencies, it helps you to optimize additional properties in pharmacokinetics and metabolic response, and/or to escape from existing patents by selecting alternative equivalent chemical groups.
[2011, Oct 1st] MEDIT eBulletin
[2011, Oct 1st] Fragment (e.g. of a drug) repurposing using MED-SuMo on a full surface PDB protein database
Fragment repurposing by mining protein structures with MED-SuMo is described in a video available in the Learning Center. The results shown are published there: Identify drug repurposing candidates by mining the Protein Data Bank. Moriaud F, Richard SB, Adcock SA, Chanas-Martin L, Surgand J-S, Ben Jelloul M, Delfaud F. Briefings in Bioinformatics Advance Access published April 21, 2011.doi: 10.1093/bib/bbr017.
[2011, June 27th] MEDIT at the BIO International Convention
MEDIT will be exhibiting at the BIO International Convention, being held in Washington DC from June 27th to June 30th, 2011. Stéphane Richard will welcome you at MEDIT booth 2505 – Hall B – France Pavilion.
[2011, May 30th] MEDIT at GGMM conference
MEDIT will be presenting at the GGMM meeting (Groupe de Graphisme et Modélisation Moléculaire), being held in La Rochelle, France from May 30th to June 1st, 2011. François Delfaud will present a poster describing our recent R&D releases titled “Applications of pairwise comparison and classification of the ligand binding sitesin protein three-dimensional structures“.
[2011, May 28th] MEDIT at the American Crystallographic Association meeting
MEDIT will be presenting at the Meeting of the American Crystallographic Association, being held in New Orleans, Louisiana from May 28th to June 2nd, 2011. Stephane Richard will present a poster describing our recent R&D releases titled “Applications of pairwise comparison and classification of the ligand binding sitesin protein three-dimensional structures“. MEDIT is welcoming you at the 211 booth.
[2011, April 22nd] New publication: Target-based repurposing of PDB ligands and PDB ligand fragments
Identify drug repurposing candidates by mining the Protein Data Bank
In this review, the target-based drug repurposing using MED-SuMo and the MED-Hybridise platform is described. The software allows browsing of the full surface of all proteins in the Protein Data Bank(PDB) and is capable of detecting site similarities and local similarities. Drug repurposing is described in terms of similar binding sites superpositions and illustrated with the repurposing of drug tadalafil from PDE5A to PDE4A. To investigate the potential of seeking for local similarities, we search a protein kinase hinge region against the full surface of all proteins in the PDB. We then retrieve experimentally validated examples including biotin carboxylase and synapsin with 60 other potential targets. Among them is the HIV-RT allosteric site which is indicating a potential application of fragment repurposing for druggable binding site detection.
- Our target-based software can identify cases of drug repurposing on a rational structural basis.
- Repurposing relies on the detection of 3D similarities between proteins and not on docking or scoring functions.
- The entire PDB can be mined exhaustively in 3D for ligand repurposing. Example of PDE4/PDE5 is provided.
- Ligand repurposing can be extended to fragments of ligand repurposing, Example of a protein kinase ligand fragment repurposed in biotin carboxylase, synapsin is given.
- The protein kinase hinge region is detected mostly, but not exclusively, in purine binding sites. Its detection in the HIV-RT non-nucleosidic allosteric site indicates that target-based fragment repurposing could serve also as a druggable site detection method.
[2011, April 12th] Oral presentation at CHI Drug Discovery Chemistry conference in San Diego
MEDIT will be presenting at the CHI Drug Discovery Chemistry, being held in San Diego, California from April 12-14, 2011. Stephane Richard will give a talk in the session Kinase inhibitor chemistry titled “Mining exhaustively the PDB enables computational Fragment-Based Drug Design”. MEDIT is welcoming you at the booth.
[2011, March 27th] Pairwise binding site classification at the 241st ACS National Meeting
MEDIT will be presenting at the The 241st ACS National Meeting & Exposition, being held in Anaheim, California from March 27-31, 2011. Stephane Richard and François Delfaud will give a poster presentation titled “Applications of pairwise comparison and classification of the ligand binding sites in protein three-dimensional structures“. MEDIT is welcoming you at the booth.
[2011, March 20th] Poster presentation on a search allergen mimotope application at the 20th West Coast Protein Crystallography Workshop
MEDIT will be presenting at the 20th West Coast Protein Crystallography Workshop, being held in Monterey, California from March 20-23, 2011. Stephane Richard will give a poster presentation titled “Drug Discovery inspired by PDB mining: repurposing of drug fragments, fragment-based drug design, search allergen mimotopes“. MEDIT is welcoming you at the booth.
[2010, Nov 6th] Poster presentation at 6th German Conference on Chemoinformatics
MEDIT will be presenting at the 6th German Conference on Chemoinformatics, being held in Goslar, Germany from November 7-9, 2010. MEDIT CSO F. Moriaud will give a poster presentation titled “Computational FBDD upon PDB: exploring the diversity and the selectivity of hybrids of PDB ligand Portions“. MEDIT is welcoming you at the booth.
[2010, Oct 4th] MEDIT is proud to announce a strategic collaboration with the Sanford-Burnham Medical Research Institute
MEDIT is proud to announce the following strategic collaboration with the Sanford-Burnham Medical Research Institute:
Sanford-Burnham Pairs with MEDIT to Design Smarter Drugs
Powerful new software matches aberrant proteins with compounds that could fix them.
LA JOLLA, Calif., October 4, 2010 – Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) are collaborating with scientists and software developers at MEDIT in France to use and enhance a new software platform built around a computer program called MED-SuMo. This platform searches protein structure databases to find compounds that bind to a particular target, and then helps optimize these “hits” to design new drugs.
“We believe that this collaboration with MEDIT significantly enhances our ability to perform structure-based drug design,” said Nicholas Cosford, Ph.D. associate professor in the Apoptosis and Cell Death Research Program in Sanford-Burnham’s Cancer Center and leader of the collaborative team. “MEDIT’s MED-SuMo software offers unique capabilities that will complement drug discovery platforms already being used in the Conrad Prebys Center for Chemical Genomics [CPCCG] at Sanford-Burnham.”
Here’s how the MEDIT technology works: Sanford-Burnham researchers select a protein they wish to target. Let’s say that this protein, Protein X, normally tells cells to divide, but when it malfunctions, it causes unchecked cell division that leads to a tumor. In an effort to uncover new anti-cancer drugs, scientists want to find compounds that bind to the deviant Protein X and turn it off. Normally, it might take months or years of work and a stroke of luck to find the one needle-in-a-haystack compound that binds and inhibits Protein X without interfering with other proteins.
Dr. Cosford and his team are taking a more targeted approach to drug design with MEDIT’s software platform. MED-SuMo takes a 3D model of Protein X and breaks it down into pieces. Then the software digs through a publically available database containing more than 60,000 proteins with known structures to find “hits” – pieces that structurally resemble parts of Protein X, but are already known to bind certain compounds. MED-SuMo superimposes the matching hits on the structure of Protein X, allowing researchers to see a 3D image of the interaction. Chemical fragments bound to the hits will bind to Protein X in a similar fashion, forming the initial building blocks for a new drug.
Once MED-SuMo puts these pieces together, MEDIT technology takes drug design several steps further. It can optimize multiple hits by finding ways they could be combined to form a single hybrid drug compound that binds Protein X better and more selectively. The system can even screen out any combinations that couldn’t realistically be generated by chemists in the laboratory, as well as those that might harm other proteins or cause toxicity in humans.
“We’re using MEDIT’s software to look for highly effective drugs,” explained Peter Teriete, Ph.D., post-doctoral researcher in Dr. Cosford’s group. “The great thing about using MED-SuMo at Sanford-Burnham is that we’re also surrounded by drug discovery experts. So if I find something that looks good on the computer, I can work with chemists and assay developers to synthesize the compound in the lab and test it to determine whether or not it has the potential to become a new drug.”
The collaboration goes both ways – Dr. Teriete and others benefit from the software and MEDIT’s engineers benefit from their feedback on what works, what could work better, and what additional features would be helpful. Their ideas and experiences will enrich future versions of the MEDIT technology platform, making it an even more powerful tool for drug discovery.
“This agreement with Sanford-Burnham, a leading scientific institution in the U.S., is a great opportunity for our company,” said Stephane Richard, Ph.D., vice president of business development at MEDIT. “The collaborative nature of the deal and the involvement of our technology in a number of structure-based drug design efforts will allow researchers at Sanford-Burnham to capitalize on our scientists’ expertise in this field.”
For more information about Sanford-Burnham research, visit http://beaker.sanfordburnham.org/.
[2010, Oct 10th] Poster presentation at Fragment-Based Lead Discovery 2010 conference
MEDIT attends FBLD 2010, being held in Philadelphia, from October 10-13, 2010. MEDIT CEO François Delfaud is presenting a poster: “Computational FBDD upon PDB: exploring the diversity and the selectivity of hybrids of PDB Ligands“. MEDIT is welcoming you at its booth.
[2010, Oct 6th] MEDIT at the Summit Series on the NAE Grand Challenges National Summit
MEDIT VP Business Development Stephane Richard is attending The Summit Series on the NAE Grand Challenges National Summit, being held in Los Angeles, from October 6 to 8, 2010.
[2010, Sept 18th] MEDIT at EuroQSAR 2010 conference: oral presentation from CSO
MEDIT is attending the EuroQSAR 2010, being held in Rhodes, Greece from September 19 to 24, 2010. MEDIT CSO Fabrice Moriaud is giving a talk in the Database mining session: “Mining exhaustively the Protein Data Bank enables computational Fragment-Based Drug Design”. MEDIT is welcoming you at its booth.
[2010 July 10th] Poster presentation on binding site clasification at Annual meeting of the ACA
MEDIT will be presenting at the 2010 Annual Meeting of the American Crystallographic Association, being held in Chicago,July 24-29. Stephane Richard will give a poster presentation titled “Fast and automated functional classification with MEDP-SiteClassifier: an application on purine-binding protein”
[2010, March 21st] Oral presentation by MEDIT CEO at 239th American Chemical Society National Meeting & Exposition
MEDIT will be presenting at the ACS spring National meeting, being held in San Francisco, California, USA from March 21-25, 2010. MEDIT CEO Francois Delfaud will give a talk on “fast PDB mining for very innovative drug design“. You will be able to discover and test our software for structure-based and Fragment-based Drug Design in our booth N°119 Hall B.
[2010, Jan 8th] Poster presentation on MEDIT R&D at Structural Biology Conference
MEDIT will be presenting at the Structural Biology Conference, being held in Breckenridge, Colorado, USA from January 8-13, 2010. MEDIT CSO F. Moriaud will give a poster presentation titled “Computational fragment-based approach at PDB scale by protein local similarity”
[2009, Nov 8th] Poster presentation at 5th German Conference on Chemoinformatics
MEDIT will be presenting at the 5th German Conference on Chemoinformatics, being held in Goslar, Germany from November 8-10, 2009. MEDIT CSO F. Moriaud will give a poster presentation titled “Computational fragment-based drug design to explore the hydrophobic sub-pocket of the mitotic kinesin Eg5 allosteric binding site
[2009, Oct 13th] Oral presentation by MEDIT CEO at eChemInfo conference 2009, Philadelphia, PA
MEDIT will be presenting at the eCheminfo conference being held in Bryn Mawr College, Philadelphia from 13-16 October 2009. MEDIT CEO Francois Delfaud will give a talk about Mitotic Kinesin Eg5 Inhibitors Generation By Computational MED-Portion Based Drug Design at PDB Scale. You will be able to discover and test our software for structure-based and Fragment-based Drug Design in our booth.
[2009, Sept 21st] Oral presentation by MEDIT CSO at Fragment-based Lead Discovery Conference 2009, York, UK
MEDIT will be presenting at the Fragment-based Lead Discovery Conference 2009 being held in York, UK from Sept. 21 – Sept. 23, 2009. MEDIT CSO Fabrice Moriaud will give a presentation.
[2009, Sept 1st] New publication: Computational fragment-based drug design to explore the hydrophobic sub-pocket of the mitotic kinesin Eg5 allosteric binding site
MEDIT presents a new work and results on Computational fragment-based drug design to explore the hydrophobic sub-pocket of the mitotic kinesin Eg5 allosteric binding site by using MED-SuMo to retrieve the best fragments and to create new ligands. This article is available on: http://www.springerlink.com/content/w524371333636u72/
[2009, July 19th] MEDIT CSO at Gordon Research Conference Computer Aided Drug Design, Tilton, NH
MEDIT will be presenting at the GRC Computer Aided Drug Design being held in Tilton, NH from July 19 – July 24, 2009. MEDIT CSO Fabrice Moriaud will give a poster presentation.
[2009, June 4th] Test our software at the Structure-based Drug Design Conference, Boston, MA
MEDIT will be presenting at the CHI Structure-Based Drug Design Conference being held in the Royal Sonesta Hotel, Boston, MA, from june 4 to june 5 2009. You will be able to discover and test our software for structure-based and Fragment-based Drug Design in our booth.
[2009, April 27th] Poster presentation on a FBDD kinesin aplication at BioIT World Conference, Boston, MA
MEDIT will be presenting at the BioIT World Conference being held in Boston, MA from April 27 – April 29, 2009. MEDIT application scientist Dr. Ksenia Oguevetskaia will give a poster presentation titled “Mitotic Kinesin Eg5 Inhibitors Generation By Computational Fragment-Based Drug Design At PDB Scale“
[2009, April 4th] Come on our booth to test our software at Fragment-Based Techniques Conference, San Diego, CA
MEDIT will be presenting at the CHI Fragment-Based Techniques being held in Hilton San Diego Resort, San Diego, CA, from April 7 to April 8 2009. You will be able to discover our latest release in our booth for MED-SuMo and pipeline pilot component.
[2008, Sept 22nd] ICSN acquires MED-SuMo technology.
ICSN (Institut de Chimie des Substances Naturelles, Gif sur Yvette, France) decided to use MED-SuMo technology to enhance its work on protein characterization and highlight structural links between proteins. MED-SuMo is a powerful molecular modelling software to compare surface interactions in few minutes toward the PDB (comparison in term of chemical features and shape).
[2008, Oct 13th] 2 oral presentations about MEDIT technologies at eCheminfo Community of Practice InterAction Meeting, Bryn Mawr College, PA
MEDIT will be presenting at the eCheminfo Community of Practice InterAction Meeting PA from 2008 October 13 to 17. MEDIT CSO Fabrice Moriaud will give a presentation titled “Exploration of the Chemical Diversity Generated by the Hybridisation of PDB Ligands” during the PDB Ligands: Analysing their Structure & Binding Data session.
Dr Charles Andrianjara from Pierre Fabre laboratories will give a presentation on the results of the CARRIOCAS project wich involves MEDIT and Pierre Fabre laboratories titled “Chemogenomic Space Exploration: Use of MED-SUMO Tools to Analyse Target and Ligand Space of the Kinome” during the In Silico based Chemogenomics session.
[2008, Sept 15th] MEDIT announces research contract with MUTABILIS biotech
Under the terms of the agreement, MEDIT will apply its molecular modelling expertise on two MUTABILIS targets to provide affinity model to optimise MUTABILIS’ proprietary molecules for their anti-infective programs.
[2008, August 17th] Oral presentation by MEDIT on FBDD across the PDB at 236th ACS National Meeting & Exposition, Philadephia, PA
MEDIT will be presenting at the 236th ACS National Meeting & Exposition being held in Philadelphia, PA from 2008 August 17 to 21. MEDIT CEO François Delfaud will give a presentation titled “A fragment-based computational protocol upon PDB to fragment library design, lead discovery and lead optimization” during the Computational Approaches for Fragment Screening session of the conference (Division of Computers in Chemistry).
[2008, July 21st] Hands-on sessions with MEDIT software at eCheminfo workshop, Oxford, UK
MEDIT will be demonstrating at the eCheminfo workshop on Drug Discovery & Planning Methods, a Hands-On Practice Approach, being held in Oxford University, Oxford, U.K. from July 21 – July 25, 2008.
[2008, June 25] MEDIT at Structure-based Drug Design Conference, Boston, MA
MEDIT will be presenting at the CHI Structure-Based Drug Design Conference being held in the World Trade Center, Boston, MA, from june 25 to june 27 2008. You will be able to discover our latest development in our booth: MED-SuMo, MED-Hybridise Lead discovery and MED-Hybridise Lead optimization and pipeline pilot component.
[2008, june 12th] MEDIT presenting Pipeline Pilot components at Accelrys 2008 Science & Technology Forums, Paris, FR
MEDIT will be presenting at the Accelrys 2008 Science & Technology Forums, being held in Paris, France the june 12th, 2008. MEDIT Application scientist L. Martin will give a presentation titled “MED-SuMo to mine the interaction surfaces in the PDB: Integration in Pipeline Pilot”. The abstract of the talk is:
“Take advantage of the structural information in the PDB and study protein interaction surface with MED-SuMo. Use our fragment database coming from PDB ligands to populate the query binding sites according to structural similarity. Then design new potential ligands with MED-Hybridiser. Here, we will show an application of both software combined to Pipeline Pilot components for Lead Discovery.”
[2008, June 1st] MEDIT at 8th International Conference on Chemical Structures, Noordwijkerhout, NL
MEDIT will be presenting at the 8th International Conference on Chemical Structures being held in Noordwijkerhout, The Netherlands, from 2008 from june 1 to june 5. MEDIT CSO F. Moriaud, will give a presentation titled “A fragment-based computational protocol at PDB scale – Application to lead-optimization of DFG-out kinase inhibitors” during the Structure-Based Drug Design and Virtual Screening session of the conference.
[2008, May 28th] MEDIT first release of a pipeline pilot component collection
MEDIT has joined others software editors in the Accelrys Independent Software Vendors (ISV) partner program.
This first release consists of three modules: MED-SuMo server, MED-Hybridise Lead discovery and MED-Hybridise Lead optimization. The modules facilitate our target based ligand generation protocol: populating a binding site with 3D fragments and generating/optimizing leads.
[2008, March 29th] MEDIT at Computer Aided Drug Design conference in Steamboat Springs, CO
MEDIT will be presenting at the Computer Aided Drug Design Keystone Symposia, being held in Steamboat Springs, Colorado from March 29 – April 3, 2008. MEDIT CEO F. Delfaud will give a poster presentation titled “A fragment-based computational protocol upon PDB to explore multiple binding pockets: Application to scaffold decoration“